Tirzepatide dosing explained: what TikTok gets right and wrong

What did @ekigiordani actually say?

Honestly? It's hard to tell. The transcript recovered from this video is garbled beyond any useful interpretation, likely the result of auto-captioning software failing on a Spanish-language video. The caption promises a breakdown of tirzepatide dosing, tagged under #glp1, #tirzepatide, and #mounjaro, but the recovered text reads like a machine hallucination about cemeteries and acting careers. No specific dosing claim, clinical statement, or medical recommendation can be reliably extracted from what was transcribed.

That's a problem worth naming directly. With 93,100 views, this video reached a real audience looking for real information about a medication that requires careful titration. Whatever was said, it mattered to those viewers. The fact that we can't verify it doesn't mean it was harmless.

Does the science back this up?

Since no verifiable medical claim was recovered, we can't evaluate the science against the transcript. What we can do is lay out what the evidence actually says about tirzepatide dosing, so viewers have a baseline to compare against whatever they heard.

Tirzepatide is a dual GIP and GLP-1 receptor agonist approved by the FDA under the brand names Mounjaro (for type 2 diabetes) and Zepbound (for weight management). The SURPASS and SURMOUNT trial series, published across multiple papers in the New England Journal of Medicine between 2021 and 2023, established the dose-escalation schedule used in clinical practice. Frías et al. (2021, NEJM) showed that higher doses produced greater HbA1c reduction and weight loss, but also more gastrointestinal side effects. The titration schedule exists specifically to manage tolerability, not just efficacy.

What did they get wrong (or right)?

We cannot confirm any specific error or accuracy because the transcript is not usable. That's the honest answer. Flagging vague or unverifiable claims is not a technicality. In the GLP-1 content space, misinformation about dosing is genuinely risky. Patients self-adjusting tirzepatide doses based on social media advice have reported nausea, vomiting, hypoglycemia in combination with other agents, and injection site complications.

What we can say is that the video's framing, a casual TikTok explaining dosing to a general audience, fits a pattern that researchers have flagged. Yeo et al. (2023, JAMA Internal Medicine) found that a significant portion of GLP-1 content on social media omitted side effect information entirely, and framed titration as simpler than clinical guidance supports. Whether this video did that, we cannot confirm. But the format invites it.

What should you actually know?

Tirzepatide dosing is not something to crowdsource from TikTok. The standard starting dose for both Mounjaro and Zepbound is 2.5 mg once weekly, with escalation in 2.5 mg increments no faster than every four weeks, up to a maximum of 15 mg weekly. That schedule is not arbitrary. It is based on tolerability data from large randomized trials. Jastreboff et al. (2022, NEJM) in the SURMOUNT-1 trial found that patients on the 15 mg dose lost a mean of 20.9 percent of body weight, but also experienced higher rates of gastrointestinal adverse events compared to lower doses.

Compounded tirzepatide, increasingly available through telehealth platforms, is not the same as brand-name Mounjaro or Zepbound. The FDA has not evaluated compounded versions for safety or efficacy. Any claim of equivalency between compounded and brand-name tirzepatide is not supported by available evidence and should be rejected outright.

• Always confirm your dosing schedule directly with a licensed prescriber.
• Dose escalation should be guided by tolerability, not by what works for someone else online.
• If you experience persistent nausea, vomiting, or abdominal pain, contact your provider before adjusting your dose.
• Tirzepatide is not approved for everyone. Contraindications include personal or family history of medullary thyroid carcinoma or MEN2 syndrome.